Management of prolymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• B-cell prolymphocytic leukemia (B-PLL) and T-cell prolymphocytic leukemia (T-PLL) are rare lymphoid neoplasms.
• These leukemias share similar presentations, including symptomatic splenomegaly and lymphocytosis, but have distinct molecular underpinnings.
• Both conditions are characterized by an aggressive clinical course, though an indolent phase may precede overt disease.

Purpose of the Study:

• To differentiate between B-cell and T-cell prolymphocytic leukemias.
• To outline current therapeutic strategies and emerging treatment options.
• To highlight recent advancements in understanding the molecular pathogenesis of these diseases.

Main Methods:

• Morphological analysis
• Immunophenotyping
• Molecular genetics evaluation
• Review of clinical data and treatment outcomes

Main Results:

• B-PLL and T-PLL can be distinguished using a combination of morphology, immunophenotyping, and molecular genetics.
• Current first-line therapies include alemtuzumab for T-PLL and purine analog-based chemo-immunotherapy for B-PLL.
• Novel agents like B-cell receptor inhibitors (ibrutinib, idelalisib) show promise for B-PLL, particularly in TP53-abnormal cases.
• Allogeneic stem cell transplantation remains a potentially curative option for eligible patients.

Conclusions:

• Accurate diagnosis through integrated methods is crucial for guiding therapy in B-PLL and T-PLL.
• Treatment strategies are evolving, with targeted therapies and immunotherapy playing an increasing role.
• Ongoing research into molecular mechanisms promises new therapeutic avenues for these aggressive leukemias.